During the past decade, BCCA-Vancouver Cancer Centre conducted 148 clinical trials. In the 10-year time frame, 148 clinical trials started and 93 clinical trials were completed, i.e. on average, 62.8% percent of trials that started reached the finish line to date. In the past 5 years, 67 clinical trials started and 47 clinical trials were completed. i.e. 70.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "BCCA-Vancouver Cancer Centre" #1 sponsor was "British Columbia Cancer Agency" with 50 trials, followed by "Canadian Cancer Trials Group" with 47 trials sponsored, "NCIC Clinical Trials Group" with 41 trials sponsored, "National Cancer Institute (NCI)" with 41 trials sponsored and "Hoffmann-La Roche" with 41 trials sponsored. Other sponsors include 88 different institutions and companies that sponsored additional 59 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "BCCA-Vancouver Cancer Centre" #1 collaborator was "National Cancer Institute (NCI)" with 25 trials as a collaborator, "AstraZeneca" with 18 trials as a collaborator, "SWOG Cancer Research Network" with 14 trials as a collaborator, "Canadian Cancer Trials Group" with 10 trials as a collaborator and "North Central Cancer Treatment Group" with 9 trials as a collaborator. Other collaborators include 232 different institutions and companies that were collaborators in the rest 151 trials.

According to Clinical.Site data, the most researched conditions in "BCCA-Vancouver Cancer Centre" are "Breast Cancer" (28 trials), "Prostate Cancer" (26 trials), "Colorectal Cancer" (8 trials), "Lung Cancer" (8 trials) and "Cancer" (7 trials). Many other conditions were trialed in "BCCA-Vancouver Cancer Centre" in a lesser frequency.

Most popular intervention types in "BCCA-Vancouver Cancer Centre" are "Drug" (235 trials), "Other" (69 trials), "Procedure" (33 trials), "Radiation" (32 trials) and "Biological" (29 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (22 trials), "Placebo" (13 trials), "Docetaxel" (11 trials), "Atezolizumab" (10 trials) and "Durvalumab" (10 trials). Other intervention names were less common.

The vast majority of trials in "BCCA-Vancouver Cancer Centre" are 202 trials for "All" genders, 47 trials for "Male" genders and 45 trials for "Female" genders.

Currently, there are NaN active trials in "BCCA-Vancouver Cancer Centre". 4 are not yet recruiting, 60 are recruiting, 64 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 135 completed trials in BCCA-Vancouver Cancer Centre, 1 suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in BCCA-Vancouver Cancer Centre, 43 "Phase 1" clinical trials were conducted, 122 "Phase 2" clinical trials and 96 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 30 trials that are defined as “Not Applicable".